<DOC>
	<DOCNO>NCT00562185</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , doxorubicin carboplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving doxorubicin together carboplatin may kill tumor cell . PURPOSE : This phase I phase II trial study side effect best dose carboplatin give together doxorubicin see well work treat patient recurrent ovarian cancer .</brief_summary>
	<brief_title>Doxorubicin Carboplatin Treating Patients With Recurrent Ovarian Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine maximum tolerate dose safety intravenous doxorubicin hydrochloride intraperitoneal carboplatin patient platinum-sensitive recurrent ovarian cancer . - To evaluate feasibility regimen patient . Secondary - To evaluate response rate progression-free survival patient recurrent ovarian cancer two prior salvage regimen . OUTLINE : This phase I dose-escalation study carboplatin follow phase II study . - Phase I : Patients receive doxorubicin hydrochloride IV 1 hour follow carboplatin intraperitoneally day 1 maximum tolerate dose achieve . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . - Phase II : Patients receive doxorubicin hydrochloride phase I carboplatin maximum tolerate dose phase I . After completion study treatment , patient follow every 4 week 1 year . PROJECTED ACCRUAL : A total 61 patient ( 18 patient phase I 43 patient phase II ) accrue study .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm ovarian carcinoma Recurrent disease Known platinumsensitive recurrent disease 2 prior salvage regimens Measurable disease define target lesion CA125 level No epithelial ovarian carcinoma low malignant potential PATIENT CHARACTERISTICS : Inclusion criterion : GOG performance status 0 , 1 , 2 Life expectancy &gt; 6 month Absolute neutrophil count ≥ 1,500/uL Platelet count ≥ 100,000/uL Hemoglobin &gt; 9.0 g/dL Creatinine ≤ 2.0 mg/dL Bilirubin ≤ 1.5 x upper limit normal ( ULN ) SGOT alkaline phosphatase ≤ 3 x ULN Neuropathy ( sensory motor ) ≤ CTCAE grade 1 Exclusion criterion : GOG performance status 3 4 Pregnant breastfeed History hypersensitivity reaction attribute conventional formulation doxorubicin hydrochloride component DOXIL® Abnormal LVEF determine gated cardiac radionucleotide scan ( MUGA ) Septicemia severe infection Acute hepatitis severe gastrointestinal bleeding Any following : Unstable angina Myocardial infarction within past 6 month NYHA class IIIV heart failure Uncontrolled angina Severe uncontrolled ventricular arrhythmia Clinically significant pericardial disease Electrocardiographic evidence acute ischemic active conduction system abnormalities Patients evidence abnormal cardiac conduction ( e.g. , bundle branch block heart block ) eligible disease stable past six month Other invasive malignancy within past 5 year except nonmelanoma skin cancer PRIOR CONCURRENT THERAPY : Inclusion criterion : See Disease Characteristics At least 6 month since prior adjuvant regimen At least 4 week since prior salvage treatment May receive secondary cytoreduction recurrent ovarian cancer May receive prior intraperitoneal therapy ovarian cancer May receive 2 prior platinum taxanebased regimen May receive prior intraperitoneal platinum frontline treatment Exclusion criterion : Prior anthracycline dose exceed 360 mg/m^2 doxorubicin hydrochloride ( include DOXIL® ) 720 mg/m^2 epirubicin hydrochloride Prior radiotherapy Prior intraperitoneal carboplatin cisplatin salvage treatment recurrent ovarian cancer Concurrent amifostine protective agent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>ovarian sarcoma</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>ovarian stromal cancer</keyword>
</DOC>